Compare NTLA & SKYT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NTLA | SKYT |
|---|---|---|
| Founded | 2014 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Semiconductors |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.8B |
| IPO Year | 2016 | 2021 |
| Metric | NTLA | SKYT |
|---|---|---|
| Price | $10.89 | $31.21 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 23 | 5 |
| Target Price | $20.02 | ★ $26.50 |
| AVG Volume (30 Days) | ★ 4.3M | 679.0K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 27.43 | ★ 1842.86 |
| EPS | N/A | ★ N/A |
| Revenue | $67,671,000.00 | ★ $442,139,000.00 |
| Revenue This Year | N/A | $40.16 |
| Revenue Next Year | $62.75 | $4.52 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 16.92 | ★ 29.18 |
| 52 Week Low | $7.95 | $8.49 |
| 52 Week High | $28.24 | $39.93 |
| Indicator | NTLA | SKYT |
|---|---|---|
| Relative Strength Index (RSI) | 32.00 | 39.06 |
| Support Level | $8.59 | $29.90 |
| Resistance Level | $15.52 | $34.40 |
| Average True Range (ATR) | 0.80 | 1.08 |
| MACD | -0.35 | 0.00 |
| Stochastic Oscillator | 10.20 | 35.07 |
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
SkyWater Technology Inc is a U.S.-based, independent, pure-play semiconductor foundry providing foundational-node manufacturing, advanced technology development, and advanced packaging services through an integrated, multi-site operating model. It operates within the United States, with fabrication and packaging facilities in Minnesota, Texas, and Florida.l. Its segments include: Legacy SkyWater: A pure-play technology foundry that offers advanced semiconductor development and manufacturing services from its fabrication facility in Bloomington, Minnesota and advanced packaging services from its Kissimmee Florida facility; and SkyWater Texas: A high-volume manufacturer that offers manufacturing services from its fabrication facility in Austin, Texas.